<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01739062</url>
  </required_header>
  <id_info>
    <org_study_id>2011-41-6904</org_study_id>
    <nct_id>NCT01739062</nct_id>
  </id_info>
  <brief_title>The ProCaRis Study: Prostate Cancer Risk Assessment in General Practice</brief_title>
  <acronym>ProCaRis</acronym>
  <official_title>Prostate Cancer Risk Assessment Using Genetic Markers in General Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Velux Fonden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The preferred method for early detection of prostate cancer (PCa) in older men with family
      history is the Prostate Specific Antigen test (PSA test), although the method is imprecise.
      It produces a high number of false-positive results and increases the risk of over-diagnosis
      and over-treatment. Yet, an increasing number of men get the PSA test as part of unsystematic
      screening. Genetic risk assessment may be a better way to identify men with low risk of PCa.
      The main study hypothesis is that genetic information about low risk of PCa can reduce the
      number of patients who get a PSA test as part of unsystematic screening.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of low risk patients who get a PSA test</measure>
    <time_frame>1 year, 2 years</time_frame>
    <description>The primary objective of this study is to evaluate the impact on use of PSA tests of introducing genetic PCa risk assessment in general practice.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Genetic risk assessment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least 40 SNP (single nucleotide polymorphisms)increase the risk of PCa. The individual risk of PCa accumulates with the increasing number of these genetic variants. The risk is doubled if patient has familial disposition as well. In retrospective studies, non-genetic risk-prediction models were compared to risk-prediction models containing both non-genetic factors and SNPs analyses. The genetic models had a significantly higher specificity than the non-genetic models. It has been argued that genetic PCa risk assessment could reduce the inexpedient use of PSA tests, saving it for patients at high risk of PCa.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Familial disposition risk assessment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic risk assessment</intervention_name>
    <arm_group_label>Genetic risk assessment</arm_group_label>
    <other_name>Single nucleotide polymorphism</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who receive a PSA test

        Exclusion Criteria:

          -  age over 80 years

          -  elevated PSA-level (&gt; 4,0 ng/ml) concurrently or within previous 2 years

          -  prostate or bladder disease

          -  prostate cancer

          -  non-Caucasians

          -  do not speak and understand Danish
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AnnBritt Brandi Krog, Cand.scient.san</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Research Unit for General Practice, Aarhus University, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flemming Bro, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>The Research Unit for General Practice, Aarhus University, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Vedsted, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Danish Research Centre for Cancer Diagnosis in Primary Care, Aarhus University, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AnnBritt Brandi Krog, Cand.scient.san</last_name>
    <phone>8716 79 15</phone>
    <phone_ext>0045</phone_ext>
    <email>abbk@ph.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Research Unit for General Practice</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AnnBritt Brandi Krog, Cand.scient.san</last_name>
      <phone>8716 79 15</phone>
      <phone_ext>0045</phone_ext>
      <email>abbk@ph.au.dk</email>
    </contact>
    <investigator>
      <last_name>AnnBritt Brandi Krog, Cand.scient.san</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Flemming Bro, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Vedsted, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>November 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PSA test</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Genetic screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

